BLAINJECTIONINJECTABLE
Approved
Aug 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
CIMERLI (ranibizumab-eqrn) by Novartis is vascular endothelial growth factor inhibitors [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIMERLI is a monoclonal antibody biosimilar to ranibizumab that inhibits vascular endothelial growth factor (VEGF), a key driver of abnormal blood vessel growth in retinal diseases. It is administered by intravitreal injection and represents a Novartis biosimilar entry into the anti-VEGF ophthalmology market. The drug treats age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.
$0.082BPart D
PeakCIMERLI is in peak lifecycle as a recent biosimilar entry; moderate team growth expected as market penetration increases against established reference products.
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CIMERLI positions you in biosimilar commercialization during peak penetration phase, requiring strong payer negotiation and provider education skills rather than traditional launch activities. Career growth is moderately constrained by the crowded competitive landscape and absence of clinical expansion opportunities, making this a lateral or slightly declining role for ambitious professionals.
Brand Manager
Worked on CIMERLI at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.